Vitamin D signaling aligns with uterine leiomyoma biology, but causality remains unproven
A new scoping review in uterine leiomyomas pulls together a wide but uneven body of evidence on the vitamin D-vitamin D receptor axis. Across 42 included studies, the pattern is consistent enough to draw attention: women with fibroids often had lower circulating 25-hydroxyvitamin D, fibroid tissue frequently showed altered vitamin D pathway signaling, and several studies linked these findings to tumor burden. Yet the picture stops short of proving that low vitamin D drives disease onset or growth. Observational signals are strong; mechanistic certainty is not.
Fibroids remain the most common benign tumors of the female reproductive tract, and their clinical burden is familiar to gynecologists who manage abnormal bleeding, pelvic pressure, infertility, and pregnancy complications. The appeal of vitamin D biology is obvious. Vitamin D acts more like a steroid hormone than a simple nutrient, and its receptor is expressed in reproductive tissue. If the pathway is disrupted, the downstream effect could plausibly reach cell proliferation, fibrotic signaling, and extracellular matrix deposition—the structural machinery that gives leiomyomas their bulk.
Lower circulating vitamin D appeared repeatedly, but confounding clouds the association
The clinical literature in this review leaned heavily in one direction. Most studies reported lower serum 25-hydroxyvitamin D concentrations in women with uterine leiomyomas than in controls, and several found inverse relationships with fibroid size, volume, or number. Those are biologically plausible associations. A deficiency in a hormone-like regulator with antiproliferative and antifibrotic activity could conceivably accompany more aggressive fibroid phenotypes.
One sentence deserves emphasis: the evidence is still mostly associative.
Fewer than half of the clinical studies adjusted for body mass index, and only one adjusted for ethnicity. That matters because both factors can shape vitamin D status and fibroid risk, especially in populations where prevalence and severity are already unequal. Cross-sectional and case-control designs also dominate the field, which means low vitamin D could just as easily reflect underlying disease, altered behavior, or shared social determinants rather than a causal driver. Measurement methods varied as well, and the review points to a recurring problem in this literature: exposure definitions are not consistent enough to make clean comparisons across cohorts.
Tissue studies point to a disrupted local vitamin D pathway
The molecular evidence sharpened the story. Seven studies examined the vitamin D-VDR axis in leiomyoma tissue and cells. Three reported reduced VDR expression, two found increased CYP24A1 expression, and two showed that calcitriol suppressed Wnt/β-catenin signaling; in one of those studies, mTOR signaling also fell. The direction of travel is notable. Lower receptor expression together with higher enzymatic inactivation of calcitriol suggests a local environment that is less responsive to vitamin D’s regulatory effects.
This is where the biology becomes clinically interesting. If leiomyoma tissue both receives less signaling through VDR and breaks down active vitamin D more aggressively through CYP24A1, then the uterine microenvironment may be set up to favor proliferation and fibrosis. In practical terms, that could allow estrogen- and progesterone-driven growth pathways to operate with less restraint. Experimental work cited in the review also indicates that calcitriol can suppress TGF-β and extracellular matrix regulation, pathways central to fibroid expansion and stiffness. The same pathway has been linked to MED12-independent effects, which widens the mechanistic relevance beyond a single molecular subtype.
Local signaling may matter more than blood levels alone
Serum vitamin D tells only part of the story. A patient can have a borderline or even adequate circulating level while the target tissue remains functionally resistant because receptor abundance is low or metabolic inactivation is high. That distinction may explain why the literature is not perfectly uniform and why some studies observe stronger associations than others. The review also notes that calcitriol can upregulate VDR expression in cultured leiomyoma cells in a dose-dependent manner, suggesting a feedback loop in which ligand exposure partially restores receptor signaling capacity.
Genetic findings were inconsistent across populations
Four genetic studies explored polymorphisms in VDR and vitamin D metabolism genes. Their results did not converge. Associations with leiomyoma susceptibility varied by population, and the review does not support a single polymorphism pattern that can be treated as reproducible across ethnic or geographic groups. That inconsistency is not surprising in a condition shaped by hormonal, genetic, and environmental inputs. It does, however, limit any attempt to use genotype alone as a clinical marker at this stage.
The review also makes an important negative point: no included study tested whether VDR mediates or modifies the relationship between vitamin D and leiomyoma. Without mediation or interaction analyses, the field cannot yet say whether VDR is the critical bridge between low vitamin D exposure and fibroid biology, or simply one part of a broader signaling network. Genetic signals may help define susceptibility, but they have not yet been tied convincingly to a clinically actionable pathway.
What the evidence map actually supports in clinic and lab
The review’s value lies in integration. Clinical data, tissue expression studies, and genetic reports all point toward the same pathway, but they do not all carry the same evidentiary weight. The clinical arm is the broadest, yet also the most vulnerable to confounding. The molecular arm is more mechanistically persuasive, yet small and heterogeneous. The genetic arm is too inconsistent to anchor strong inference. Taken together, these findings justify continued work on the vitamin D-VDR axis, but not clinical overreach.
For bedside practice, the most defensible reading is cautious. Vitamin D status may be relevant in women with fibroids, particularly in research settings or in patients with known deficiency, but this review does not establish vitamin D as a treatment for leiomyomas. It does reinforce the need for better phenotyping, better exposure measurement, and studies that sample blood and tissue at the same time. Future cohorts will need LC-MS/MS vitamin D measurement, full confounder adjustment, and longitudinal follow-up if the field wants to move from association to mechanism.
The protocol for the review was prospectively registered on the Open Science Framework, and the final article was published in PLOS ONE by Katamba and colleagues in 2026. The citation trail is clear; the clinical next step is not. What remains missing is a study design capable of showing whether vitamin D signaling is a driver of fibroid biology, a marker of disease burden, or both.
- • PLOS ONE DOI 10.1371/journal.pone.0363360: https://doi.org/10.1371/journal.pone.0363360